Misbah Tahir is CFO at IGM Biosciences, Inc. (IGMS). They have made 13 open-market trades across 1 company since 2022, most recently 2025-07-23.
CIK 0001787359
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| IGMS | 170,061 | $216K |
Shares reported on the most recent Form 4, priced at the 2025-07-25 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IGMS | SELL | 2025-07-23 | 2025-07-25 | $1.27 | $11K | +0.8% | N/A | N/A |
| IGMS | SELL | 2025-06-16 | 2025-06-20 | $1.20 | $2K | +14.8% | +11.3% | N/A |
| IGMS | SELL | 2025-03-14 | 2025-03-18 | $1.23 | $9K | +1.6% | +0.0% | +0.0% |
| IGMS | SELL | 2024-12-16 | 2024-12-18 | $7.48 | $13K | -14.2% | -75.1% | -83.1% |
| IGMS | SELL | 2024-09-13 | 2024-09-17 | $11.54 | $17K | -4.3% | -9.8% | -58.4% |
| IGMS | SELL | 2024-06-14 | 2024-06-18 | $7.58 | $12K | -5.0% | +49.8% | +121.5% |
| IGMS | SELL | 2024-03-13 | 2024-03-15 | $10.02 | $54K | -11.6% | -10.3% | -24.3% |
| IGMS | SELL | 2023-11-27 | 2023-11-29 | $5.06 | $7K | -8.4% | +22.7% | +109.9% |
| IGMS | SELL | 2023-05-23 | 2023-05-25 | $12.31 | $15K | -6.9% | -20.9% | -30.5% |
| IGMS | SELL | 2023-03-14 | 2023-03-16 | $18.73 | $33K | -10.3% | -36.0% | -45.1% |
| IGMS | SELL | 2022-12-16 | 2022-12-20 | $19.62 | $119K | -14.7% | +18.4% | -16.0% |
| IGMS | SELL | 2022-11-23 | 2022-11-28 | $21.57 | $19K | +3.7% | -19.9% | +7.5% |
| IGMS | SELL | 2022-05-26 | 2022-05-26 | $17.10 | $16K | +13.0% | +17.1% | +24.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.